MediGene AG (ETR:MDG1) has been given a €12.00 ($14.12) target price by equities research analysts at Oddo Securities in a research note issued on Tuesday. The firm currently has a “buy” rating on the stock.
A number of other equities analysts have also commented on MDG1. Independent Research GmbH set a €12.00 ($14.12) price target on shares of MediGene AG and gave the stock a “neutral” rating in a research report on Saturday, May 20th. Baader Bank set a €19.00 ($22.35) price target on shares of MediGene AG and gave the stock a “buy” rating in a research report on Saturday, May 20th.
Shares of MediGene AG (ETR:MDG1) opened at 9.82 on Tuesday. MediGene AG has a 12 month low of €6.65 and a 12 month high of €15.19. The stock’s 50 day moving average is €10.81 and its 200 day moving average is €11.64. The firm’s market capitalization is €197.85 million.
About MediGene AG
Medigene AG is a Germany-based biotechnology company that develops treatment platforms to target various types and stages of cancer with candidates in clinical and pre-clinical development. The Company focuses on the development of personalized T cell-based immunotherapies. It develops three platforms: T-cell receptor (TCR)-modified T cells for adoptive T-cell therapy as treatments for patients with tumor burdens; Dendritic cell (DC) vaccines for the treatment of low tumor burdens, such as minimal residual disease or for use in combination therapies, and T-cell-specific monoclonal antibodies (TABS) to identify T cells based on their T-cell receptors.
Receive News & Ratings for MediGene AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MediGene AG and related companies with MarketBeat.com's FREE daily email newsletter.